- Home
- CLDI vs EVOK Comparison
CLDI vs EVOK Comparison
Compare CLDI & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- EVOK
- Stock Information
- Founded
- CLDI 2014
- EVOK 2007
- Country
- CLDI United States
- EVOK United States
- Employees
- CLDI N/A
- EVOK N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- EVOK Health Care
- Exchange
- CLDI Nasdaq
- EVOK Nasdaq
- Market Cap
- CLDI 8.7M
- EVOK 7.6M
- IPO Year
- CLDI N/A
- EVOK 2013
- Fundamental
- Price
- CLDI $1.49
- EVOK $10.70
- Analyst Decision
- CLDI
- EVOK
- Analyst Count
- CLDI 0
- EVOK 0
- Target Price
- CLDI N/A
- EVOK N/A
- AVG Volume (30 Days)
- CLDI 231.9K
- EVOK 235.3K
- Earning Date
- CLDI 11-07-2025
- EVOK 11-07-2025
- Dividend Yield
- CLDI N/A
- EVOK N/A
- EPS Growth
- CLDI N/A
- EVOK N/A
- EPS
- CLDI N/A
- EVOK N/A
- Revenue
- CLDI N/A
- EVOK $12,794,859.00
- Revenue This Year
- CLDI N/A
- EVOK $57.38
- Revenue Next Year
- CLDI N/A
- EVOK $59.57
- P/E Ratio
- CLDI N/A
- EVOK N/A
- Revenue Growth
- CLDI N/A
- EVOK 70.02
- 52 Week Low
- CLDI $1.10
- EVOK $1.94
- 52 Week High
- CLDI $46.68
- EVOK $10.79
- Technical
- Relative Strength Index (RSI)
- CLDI 47.51
- EVOK 84.11
- Support Level
- CLDI $1.10
- EVOK $4.50
- Resistance Level
- CLDI $1.56
- EVOK $10.73
- Average True Range (ATR)
- CLDI 0.14
- EVOK 0.25
- MACD
- CLDI 0.01
- EVOK 0.55
- Stochastic Oscillator
- CLDI 69.49
- EVOK 98.25
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.